ClinicalTrials.gg
RecruitingNCT07089134Updated Sep 15, 2026

Virtual Reality in Intensive Care Unit: Patient Satisfaction, Clinical and Functional Outcomes, Feasibility

An interventional study of reabilitação fisioterapêutica tradicional and fisioterapia utilizando realidade virtual imersiva in Hospitalized Patients, ICU Hospitalization and Intensive Care Unit-acquired Weakness, sponsored by Hospital Sirio-Libanes. Recruiting at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by Hospital Sirio-Libanes · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Background: Virtual reality is recognized as a progressive technology with the potential to enhance the rehabilitation process. Immersive virtual reality-based treatments can improve motor outcomes in physical rehabilitation, reduce stress caused by the intensive care unit environment and maximize patients' recovery processes.

Objective: To analyze the efficacy of rehabilitation using immersive virtual reality on patient satisfaction and experience, functional and clinical outcomes and the feasibility of its application during the hospitalization period in an intensive care unit (ICU).

Methods: This is a randomized controlled clinical trial involving ICU patients aged 18 years or older, with an estimated ICU stay of ≥ 72 hours, the ability to understand and follow verbal instructions and no diagnosis of psychotic disorders, visual impairment, or hearing loss. Patients will be divided into two groups: one undergoing traditional physiotherapy rehabilitation - control group (CG), and the other receiving physiotherapy using immersive virtual reality (IVR group). The following evaluations will be conducted: mobility condition, physical and psychological discomfort, estimated physical activity level, occurrence of delirium, cognitive decline screening, functionality classification, motivation level, patient experience, sense of immersion in the virtual reality environment, patient satisfaction during the rehabilitation process, occurrence of adverse events, and protocol feasibility. Data will be presented in graphs and tables. Results will be considered statistically significant at a 5% significance level (p ≤ 0.05), and all analyses will be performed using SPSS Statistics version 22.

Expected results: The investigators expect to find evidence that rehabilitation using immersive virtual reality can promote and enable a more pleasant and less traumatic experience during the patient's hospitalization, with greater satisfaction and adherence to the proposed rehabilitation, in addition to being an effective tool to optimize patients' functional and clinical outcomes.

02

Conditions studied

  • Hospitalized Patients
  • ICU Hospitalization
  • Intensive Care Unit-acquired Weakness

Browse trials for

Keywords

  • virtual reality
  • rehabilitation
  • intensive care
  • stress
  • satisfaction
  • patient experience
03

In context

Personal Satisfaction

541 studies on the registry are indexed under Personal Satisfaction; 93 are open to participants now.

This study's planned enrollment of 90 is close to the median of 93 across 416 interventional studies indexed under Personal Satisfaction.

Browse Personal Satisfaction studies →

Lead sponsor

Hospital Sirio-Libanes is the lead sponsor of 44 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥18 years
  • Glasgow Coma Scale (GCS) score ≥14
  • Richmond Agitation-Sedation Scale (RASS) score between -1 and +1
  • Negative for delirium according to the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU)
  • Estimated ICU stay of ≥72 hours
  • Able to communicate in Portuguese
  • Understand and follow verbal instructions
  • Have no psychotic disorders, visual impairment or hearing loss.

Exclusion criteria

Exclusion Criteria:

  • Hemodynamic instability
  • Signs of respiratory distress
  • Contact isolation for infectious diseases
  • Conditions that limit head and neck movement
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Active comparator
    traditional physiotherapy rehabilitation

    The traditional physiotherapeutic rehabilitation protocol will be guided by the characteristics of the early rehabilitation protocol in the ICU, structured by the rehabilitation service of Hospital Sírio-Libanês. This protocol provides recommendations for effective and applicable exercises based to the clinical reality, serving as a guiding resource in the care of critically ill patients.

    Procedure: reabilitação fisioterapêutica tradicional

  • Experimental
    physiotherapy using immersive virtual reality

    The immersive virtual reality physiotherapeutic rehabilitation protocol will employ 3D virtual reality headset that simulate human sensory input to create an immersive environment.

    Procedure: fisioterapia utilizando realidade virtual imersiva

Interventions

  • Procedurereabilitação fisioterapêutica tradicional

    Active and passive exercises, and walking

  • Procedurefisioterapia utilizando realidade virtual imersiva

    Use of immersive virtual reality headset for rehabilitation sessions

06

What researchers measure

Primary outcomes

  1. Patient satisfaction

    To assess patient satisfaction, the investigators will use the Net Promoter Score (NPS) method, it is a methodology that indicates the likelihood of a consumer recommending products or services to others. The results are interpreted using the following parameters: 75-100% is considered "excellent," 50-74% is classified as "very good" and below 49% as "poor."

    Time frame: Day 1 and day 7 or intensive care unit discharge

  2. Patient experience: Perceived workload

    To evaluate patient experience, the Raw Task Load Index (RTLX) will be used to assess perceived workload during or immediately after rehabilitation sessions. It is a multidimensional scale scored from 0 to 100, with higher scores indicating greater cognitive load.

    Time frame: Day 1 and day 7 or intensive care unit discharge

  3. Patient experience: Perceived motivation

    Perceived motivation will be assessed using the Intrinsic Motivation Inventory (IMI), a 7-point Likert scale evaluating the individual's subjective experience during an activity (1 = strongly disagree; 7 = strongly agree).

    Time frame: Day 1 and day 7 or intensive care unit discharge

  4. Patient experience: Perceived presence

    Patients in the immersive virtual reality group will also complete the Presence Questionnaire (PQ), a self-report tool that measures perceived presence in the VR environment across four domains: Engagement, Immersion/Adaptation, Sensory Fidelity, and Interface Quality. The PQ uses a 5-point Likert scale, with higher scores reflecting a stronger sense of presence.

    Time frame: Day 1 and day 7 or intensive care unit discharge

Secondary outcomes

  1. Classification of physical activity level

    Physical activity assessment will be conducted using the International Physical Activity Questionnaire (IPAQ). The short version consists of seven open-ended questions, allowing estimation of the time spent per week in different dimensions of physical activity (walking, moderate and vigorous activities) and physical inactivity (sitting time). Based on IPAQ scoring guidelines, patients can be classified as: very active, active, irregularly active, or sedentary.

    Time frame: Baseline

  2. Muscle Strength

    Muscle strength will be assessed using the Medical Research Council (MRC) manual muscle test. This evaluation involves testing key upper limb muscles (shoulder abduction, elbow flexion, wrist extension) and lower limb muscles (hip flexion, knee extension, ankle dorsiflexion) against the examiner's resistance. Strength is rated on a scale from 0 (no muscle activation) to 5 (full range of motion against full examiner resistance). Classification is based on the degree of muscle contraction or range of motion for each muscle evaluated. The total score ranges from 0 (complete tetraparesis) to 60 points (normal muscle strength).

    Time frame: Baseline and after 7 days or intensive care unit discharge

  3. Mobility Assessment

    Patient mobility will be assessed using the ICU Mobility Scale. This scale ranges from 0 to 10 within a single domain, where a score of 0 indicates very low mobility (e.g., the patient performs only passive exercises in bed), and a score of 10 indicates high mobility (e.g., the patient walks independently without assistance).

    Time frame: Baseline and after 7 days or intensive care unit discharge

  4. Functionality Classification

    The International Classification of Functioning, Disability and Health (ICF) will be used to describe functionality and disability related to health conditions, considering body functions and structures, activity limitations, and participation restrictions in the patient's environment. A customized checklist adapted to the ICU context of Hospital Sírio-Libanês will be used in this study. Qualifiers specify the level of functioning, ranging from 0 (no impairment) to 4 (complete impairment). Codes 8 and 9 indicate lack of information or not applicable. In the body structure category, three qualifiers are used to describe the nature of the impairment. In the activity and participation category, two qualifiers are used: performance and capacity. For environmental factors, a positive score (1 to 4) indicates facilitators, while a negative score (-1 to -4) indicates barriers.

    Time frame: Baseline and after 7 days or intensive care unit discharge

  5. Delirium Assessment

    The diagnosis and monitoring of delirium during ICU stay will be performed using the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). This is a quick and accurate tool for diagnosing delirium in critically ill patients, combining sedation and delirium monitoring.

    Time frame: Up to 7 days or intensive care unit discharge

  6. Cognitive Function Assessment

    Cognitive functions will be assessed using the Montreal Cognitive Assessment (MoCA), a brief screening tool that evaluates a wide range of cognitive domains, including executive functions, visuospatial abilities, naming, memory recall, digits, sentence repetition, abstract reasoning, and orientation. MoCA is considered effective for detecting mild cognitive impairment and dementia. The test is simple and quick to administer, taking approximately 20 minutes. The maximum score is 30 points, with a cutoff of 26; scores above 26 are considered normal.

    Time frame: Baseline and after 7 days or intensive care unit discharge

  7. Assessment of Pain and Psychological Variables

    To assess discomfort, the Numeric Rating Scale (NRS) will be used. This is a unidimensional tool that measures discomfort intensity and is suitable for conscious and communicative adult patients. Assessments will be performed before and after the rehabilitation protocol. For pain assessment, patients will be asked to rate their pain on a scale from 0 to 10, where 0 represents no pain and 10 indicates the worst possible pain. The same scale will be used to evaluate the perception of anxiety and stress, quantifying the intensity of these psychological variables.

    Time frame: Baseline and after 7 days or intensive care unit discharge

  8. Rehabilitation Protocol Feasibility

    The feasibility of the protocol will be measured through the adherence rate to immersive virtual reality therapy sessions. Adherence will be calculated as a percentage (%) using the formula: number of rehabilitation sessions completed / total number of eligible sessions × 100. In this study, a value above 70% will be considered indicative of good feasibility of the rehabilitation protocol.

    Time frame: After 7 days or intensive care unit discharge

  9. Adverse Events: Fall risk

    Fall risk will be assessed using the Johns Hopkins Fall Risk Assessment Tool. This scale stratifies and establishes personalized preventive measures for hospitalized patients. The total score categorizes patients as low risk (0-5 points), moderate risk (6-13 points), or high risk (14-35 points).

    Time frame: Up to 7 days or intensive care unit discharge

  10. Adverse Events: Presence of symptoms

    The presence of symptoms will be evaluated using the Simulator Sickness Questionnaire (SSQ), which assesses the presence and intensity of 16 symptoms, including general discomfort, fatigue, headache, eye strain, difficulty focusing, increased salivation, sweating, nausea, poor concentration, "heavy head," blurred vision, dizziness (eyes open/closed), vertigo, abdominal discomfort, and belching. Symptom intensity is rated as 0 (none), 1 (mild), 2 (moderate), or 3 (severe).

    Time frame: Up to 7 days or intensive care unit discharge

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Aug 2028, 23 months after the start.

Of 248 non-industry interventional studies with no phase under Personal Satisfaction, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 21. This study's planned 23 months is above that.

Counting every sponsor, half of 255 studies reached it within 9 months; a quarter within 3 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2025
First posted
Jul 28, 2025
StartActual
Sep 1, 2026
Primary completionEst.
Aug 30, 2028
CompletionEst.
Oct 30, 2028
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07089134
Lead sponsor
Hospital Sirio-Libanes
Responsible party
Wellington Yamaguti (Principal Investigator, Hospital Sirio-Libanes) — Principal investigator
First posted
Jul 28, 2025
Start date
Sep 1, 2026
Primary completion
Aug 30, 2028 (estimated)
Completion
Oct 30, 2028 (estimated)
Last update
Sep 15, 2026

Study contacts

Wellington Yamaguti, PHD
Contact
wellington.psyamaguti@hsl.org.br
1133940200 ext. 4395
Manoella C Andrade, Dra
Contact
manoellacavalcantedeandrade@gmail.com
11950739911 ext. 4395
Wellington Yamaguti, PHD
principal investigator · Hospital Sirio-Libanes

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion